Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 3/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3370759 | 0.88 | AGER (0.55) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL16908761 | 0.86 | C5AR1 (0.51) | AGEROPRM1L3MBTL1MEN1KMT2A | |
| SCHEMBL28019674 | 0.85 | CCR5 (0.47) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL803784 | 0.84 | CCR5 (0.45) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL2814615 | 0.83 | AGER (0.67) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL17352482 | 0.83 | CTSD (0.50) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL1964546 | 0.82 | HSD11B1 (0.53) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL562409 | 0.81 | AGER (0.48) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL736914 | 0.81 | AGER (0.50) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL736913 | 0.81 | AGER (0.50) | AGERMTNR1ACHRM2CHRM3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120035213-A1 | Quinoline derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-02-09 | — | — | US | disclosed |
| WO-2011117798-A1 | 3-(HETEROARYL-AMINO)-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-7160894-B2 | Antagonist of phosphorylation of myosin regulatory light chain, enzyme inhibitors; therapeutic treatment of glaucoma, bronchial asthma, chronic obstructive pulmonary disease, nervous system disorders; 4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamine | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-01-09 | — | — | US | disclosed |
| EP-1632492-A1 | TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2006-03-08 | — | — | EP | disclosed |
| US-20050096310-A1 | Tricyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096310-A1 | Tricyclic compound | MYLK3, CSNK1A1L, MYLK | AGER 4712/4885MTNR1A 527/4885CHRM2 42/4885 |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | CDC7, CDK7, DTYMK | AGER 3825/4885MTNR1A 4590/4885CHRM2 4859/4885 |
| US-20120035213-A1 | Quinoline derivative | MC1R, MCHR1, MCHR2 | AGER 2254/4885MTNR1A 12/4885CHRM2 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.